Client Login


Benning Associates' principals have an unusually large amount of successful transaction experience.

The principals of Benning Associates have advised on over 200 transactions for an aggregate value of $40 billion, with sizes ranging from $10 million to over $1 billion. More than two-thirds of our transactions have occurred between $25 million and $100 million in value. We excel at highly structured and complex transactions, as well as running meticulously executed corporate sale processes.

We believe our independence, senior professional focus, industry knowledge and experience allow us to provide advice in change of control situations that lead to enhanced shareholder value, with less transaction risk. At Benning Associates, our focus is on building the firm from references, one client at a time.

Selected Client Successes


$55M - Public:Public

Sellside Advisory, Fairness Opinion.

Competitive sale of DirectSelect drug discovery technology at 150% premium to market stock price to Glaxo Smith Kline.

Read Press Release


$155MM - Cross-border, Public:Public

Divestiture, Special Committee Advisory, Fairness Opinion

Assisted Curagen in review of strategic alternatives & sale of high-profile genome sequencing subsidiary, 454 Life Sciences to Roche.

Read Press Release


$30MM - Public:Private

Special Committee Advisory, Valuation, Fairness Opinion

Advisory and opinion related to private financing round for 454 Life Sciences independent subsidiary.


$94MM - Cross-border, Private:Private

Sellside Advisory

Competitive sale of German venture-backed LVAD manufacturer to Syscore GmbH.

Read Press Release


$74MM - Cross-border, Public:Private

Buyside Advisory; Fairness Opinion

Negotiated acquisition of heart recovery micro-pump manufacturer Impella CardioSystems AG. Complex collar/CVR deal consideration.

Read Press Release


Terms Confidential - Public:Private

Sellside Advisory

Competitive sale of family-owned industrial and medical high-reliability interconnect manufacturer to Amphenol.

Read Press Release

back to top